Promomed received approval for the first product in the anti-cancer portfolio targeting widespread cancers

Capecitabin-Promomed used in the treatment of cancer received marketing authorization certificate and became the first product in the anti-cancer portfolio of Promomed Group.

The development and production of anti-cancer drugs is an important strategic direction of the Promomed Group with its focus on solving significant medical problems, saving and significantly improving the quality of life of patients.

«The development in the oncology sector requires great efforts from the whole team: it includes expansion of production, development of personnel, and, of course, extensive scientific and research activity. Part of this path has already been passed, the first results have been achieved and the first approval has been obtained,» commented Petr Bely, Chairman of the Board of Directors of Promomed Group.

Capecitabin is a first-line drug for the treatment of stomach and colon cancer and is widely used for the treatment of breast cancer resistant to other types of chemotherapy.

It has a selective antitumor effect, mainly on the affected cells, while the effect on healthy tissues is minimal. Thanks to the quality of the substance and modern production technologies, Promomed Group provides high efficacy and an improved safety profile of medicines.

«In cancer therapy, drug safety is a significant reserve for improvements. In each of the chemotherapy lines, starting with the second one, adverse events associated with the use of drugs begin to compete with or even overweight the therapeutic benefit. Accordingly, if we improve the tolerability of drugs, then a larger number of patients can be cured or increase life expectancy with proper quality,» Petr Bely said.

Capecitabin-Promomed is available in the form of film-coated tablets, 150 and 500 mg, which corresponds to the treatment regimens. The drug is included in the list of vital and essential drugs.